Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance

Source : https://link.springer.com/article/10.1007/s12254-021-00689-2

AL amyloidosis (AL) and monoclonal gammopathy of renal significance (MGRS) are both paraprotein-associated diseases. Both entities are based on a monoclonal paraprotein produced by a clonal plasma-cell population like in...

Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review.

Source : https://europepmc.org/article/med/33518613

Few reports have so far described central nervous system (CNS) involvement in multiple myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments. We herein describe...

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma

Source : https://www.mdpi.com/1422-0067/22/3/1341/htm

Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance...

Immunodeficiency Secondary to Malignancies and Biologics

Source : https://link.springer.com/chapter/10.1007/978-3-030-57157-3_21

S. Shahzad Mustafa There are many causes for secondary immunodeficiency (SID), which commonly presents with increased risk of infections. B-cell malignancies (multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin's lymphoma) and chemotherapeutics...

Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye

Source : https://doi.org/10.1080/10428194.2021.1873320

Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional...